In particular, nuclear matrix protein 22 (NMP22) is often observed in the urine of patients with urothelial cancer [76] and its use has been therefore approved by the FDA as a monitoring tool for detecting transitional cell carcinoma (TCC) of the bladder [77,78]. The gene discussed is NUMA1; the disease is transitional cell carcinoma.